The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
Pathophysiological changes influenced by multiple factors in critically ill patients, has a
significant impact on pharmacokinetics (PK) and pharmacodynamics (PD) of cisatracurium. In
order to understand better and find an appropriate dosing regimen, the purpose of this study
is to investigate the PK and PD of a loading dose cisatracurium in critically ill patients.
Cisatracurium, nondepolarizing neuromuscular blocking agents (NMBAs), are commonly used in
intensive care units because of a lesser effect on hemodynamic parameters and a reduction in
mortality rate in ARDS patients. Loading dose recommended in clinical practice guidelines for
sustained neuromuscular blockade in the adult critically ill patient is 0.1-0.2 mg/kg. Then,
maintenance dose of 1-3 mcg/kg/min is followed regarding indications, such as ARDS. However,
this recommended loading dose might not be adequate in critically ill patients, the study in
this specific population might be needed.